🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Mettler-Toledo International Inc. (MTD)
NYSE: MTD · Real-Time Price · USD
1,737.26
+24.31 (1.42%)
At close: Nov 18, 2026, 4:00 PM EST
1,736.39
-0.87 (-0.05%)
After-hours: Nov 18, 2026, 4:52 PM EST
← View all transcripts

Stifel 2026 Healthcare Conference 2026

Nov 12, 2026

Summary

Investment in R&D, digital platforms and supply-chain resilience supports product innovation and AI-enabled customer workflows. Replacement demand is improving, while China momentum and long-range growth plans are balanced by tougher comparisons and volume-dependent margin leverage.

Speaker 1

We are on the life sciences side with Mettler-Toledo International. Happy to have CFO Shawn Vadala with us today. Shawn, thanks very much for spending some time.

Shawn Vadala
CFO, Mettler-Toledo International

Yeah. Hey, thanks, Dan. It was great to see you. It was great to see everybody. Thanks for hosting us today.

Speaker 1

Yep. Busy week or last week or so for you guys and for us. You reported earnings on Friday. It was a good quarter. Then we were down in Tampa for your Investor Day. Maybe that is a good place to start. It was the first one in four years. Can you just little talk about the message there and what you think were the most salient points coming out of that? What you think we should know as investors and analysts?

Shawn Vadala
CFO, Mettler-Toledo International

Yeah. I think to me, there was a few things that stood out. I think we covered a lot of ground there. The first message is that we've been investing quite a bit in the business over the last few years. We tried to really outline that. It starts with R&D and innovation. We've increased our R&D spending by 32% in the last five years. That's led to increasing our value proposition to our customers, but also a lot of new products. If you kind of listen to our quarters over the last couple years, you might have picked up that we're talking a little bit more about examples of new product introductions. That's, I think, extremely important, and it's been well received in the market.

The second area that we've been investing in is digitalization. This is not a new topic for us. We've been investing in the Blue Ocean program for 20 years. It provides a really strong platform for us internally. If you think about it, one single instance of an IT infrastructure, with harmonized global processes. That gives you, it allows you to automate things, but it also gives you the data, right? The data that you need to gain the insights. Now that we have new technologies like AI, we can kind of go to that next level. We talked about that. We talked about some of the new growth initiatives that we have introduced in the last few years, like in the service organization, as an example.

The last area that we've been investing in is resilience. Like most companies around the world, as we're coming out of COVID, we wanted to have a more resilient supply chain. As we were thinking about that, we wanted to have more flexibility in that supply chain, and we wanted to be able to be a little bit closer to our customers. Now with the onset of tariffs, of course, we've had to accelerate a lot of those investments as well too. But sitting here today, it's nice having a more flexible, agile supply chain. That was category number one. Category number two is, I feel like, even though the algorithm is very much the same as we might have talked about in the past, the number of drivers is much more.

If you think about all the different types of growth drivers that we outlined during the Investor D ay, that's what gets me really excited. There's just a lot of more opportunities to kind of get to Rome, if you will. We kind of went through each one of those. I'm sure you'll kind of want to dig into some of that, so I won't go into too much detail now. Whether it be a better mix in the business, whether it's trends in automation and digitalization, whether it's some of these hot segments, there's just a lot of great opportunities in the business, including the onshoring opportunities. The last thing is I just think we're just very well positioned for the future. We have really strong return on invested capital, strong free cash flow, and I think we're very much prepared for the future.

Speaker 1

Yeah. Maybe just on the automation and digitization point, because you are right, that has something that has been a tailwind for you guys longer than the AI conversation has been what it is right now. Can you maybe separate out, A, where that trend is accelerating for you, and the idea would be 2027 is a year where you have more of that working for you as an organic growth driver. Then, B, how AI does play into that, and what customers are actually prepared to handle AI capabilities that you might enable?

Shawn Vadala
CFO, Mettler-Toledo International

Yeah. Hey, great question, and that third category really is getting to the heart of it, is being prepared for the future really is about having the right platform to support our customers, whether it be with their AI programs, whether it is their automation needs, their digitalization needs, but also the platform internally, to whether it is how we develop products, how we engage customers, or how we gain more insights and productivity within Mettler-Toledo. As you think about it, in terms of supporting customers, one of our strengths is that we serve them throughout their value chain. You think about R&D all the way through production. We have a broad offering of instruments. We have all these instruments and also sensors that collect information, right?

Then on top of that, though, we have the software data layer. We have LabX software in the laboratories, but we also have industrial terminals in the production environment. That is really critical because when you have a broad range of instruments and you have one software application to collect all that, it can do it in a very structured way, a validated way, a compliant way that really is impactful for our customers, but it also helps them with their own AI programs, right? Or their automation programs. We gave an example that you saw at the Investor Day of an example of what an autonomous lab could look like, right? In an autonomous lab, there is a wide range of different types of instruments.

Any day you can do a different combination of different types of instruments. We're pretty fortunate because we have some of the most commonly used instruments in a lab, whether it be a laboratory balance or a pipette for liquid handling. We can enable most of our instruments with LabX, and then we partner with external robotics companies, right? LabX is the tool that communicates with the robot. It enables the workflow automation, but it's also collecting the data during the process that it can then feed into their AI program. That's just one example. Of course, we're doing a lot of things in the industrial environment. We're doing things in bioprocessing, like with process analytics that you would have seen. In the end, there's a lot of things that we're doing for our customers to enable their own AI programs.

The other side of it is, like, how are we using that internally? I can't remember the full part of your question, but maybe I'll go in that direction too, is like we're also using AI internally in terms of how we provide products to the market. If you think about some of those examples that we had the other day with imaging technologies or advanced algorithms or whatever, there's a lot of things that we can do to add value to our customers with our products. We have embedded AI wizards, as an example, in some of our analytical instruments. The second category is how we're using it to engage customers with a more digital experience. The third category, of course, is how we're leveraging it internally.

We have, I think, like 5,000 agents at the moment deployed with over 100 use cases through all the different functional areas in the company. When we do that, of course, there's productivity involved, but I think to me what gets me excited is the insights that we're getting out of the business to be able to innovate faster and ultimately support our customers.

Speaker 1

Yeah. Okay. All right. Let me maybe try and come back to AI at the end, because I think people would like to hear you talk about just how that's going to be a good guy for you, I mean, across the board, but also just for the two sides of the business. Before we do that, I want to just talk about instrument replacements, which you touched on. At the Analyst Day, it was, I thought, pretty clear that the way that you're thinking about the instrument cycle now is different than it was a year or two ago. Amazingly, we're still talking about this as being like a post, the coming out of the COVID period.

How do you see the instrument replacement cycle today, or into 2027, when it comes to just accelerating demand and thinking about who might be willing to replace an instrument that wasn't last year or two years ago? The corollary to that would just be, are you seeing new sources of instrument demand, just given the automation trend that we're talking about here?

Shawn Vadala
CFO, Mettler-Toledo International

Yeah. So, yeah, good way to end it as well with the question. So, in terms of replacement demand, we were encouraged last quarter when we started to see categories like analytical instruments pick up, laboratory balances. Think about the instruments that typically around a QA/QC bench. That's where we started to see in Q2 the business really picking up, and it was nice to see that trend kind of continue into the third quarter. It's hard to tell exactly how much is replacement or not, but we felt like these are the categories that we would see first, and so that was kind of nice to see. As we guide Q4 and we start to think about how we'll start next year, it feels to us like that trend will continue.

When we kind of step back from the whole thing, you think about what was our business pre-COVID? What did it take to grow this business? In the Western markets, it was pretty much customers sticking to their replacement cycle. I mean, 80%-90% of what we did was really customers sticking to their replacement cycle. So, just getting back there is actually a pretty big deal for us. When you kind of look at the most recent time period, we kind of showed a slide the other day that showed 2021, our sales went up 18%, and then in 2022, they went up 12%.

W e kind of had, like a lot of companies, just a lot of extra replacement that was happening, maybe an acceleration of replacement cycle that happened in those two years, which is kind of unique for our space. Then there was kind of like the aftermath here. But now if you think about, like, what's the average age of an instrument? It tends to be anywhere from five to 10 years, depending on the use and the environment. We typically say that the average is around seven years, but it can be more or less. But if now you start to do some simple math on that time period, it kind of makes sense, right?

Like, we might be at the very beginning early of something that might be in that five-year range, but the sweet spot will be more in that probably seven-year kind of range, but could have a tail out to 10 years. Now, of course, some things can last longer, but that's kind of like how we're looking at that. Just that alone should be a meaningful thing. And like you said, in addition to that, we do have new investment opportunities. Our customers investing, I mean, automation and digitalization, it's clearly an important trend.

And maybe coming back to your first question, like, if I look at the parts of our business that are performing the best, they're the products categories that directly support our customer automation and digitalization needs. And when you really go under the covers of the industrial business, you'd see those categories doing very well. We have a little bit of project topics with some other businesses. Like last year, we had that tough comp that maybe kind of makes that not so obvious, but we really have very good trends there, and they're global trends, but we also see it in the lab as well too.

Speaker 1

Yeah. I would also imagine that if you're a lab and you're looking to your left and you're looking to your right and both guys are replacing their instruments with the idea that they need AI enablement, you're likely to do the same thing, sort of to keep up with the Joneses. I don't think Mettler-Toledo gets compared to a next-gen sequencing company all that often, but it does seem like this idea where you kind of have to make sure that you're on par with where others are going, even if you weren't thinking about buying that box in the next six months.

Would you agree with that, or would you say that the peer pressure is less than maybe what I'm making it out to be?

Shawn Vadala
CFO, Mettler-Toledo International

Mean for our customers, you mean?

Speaker 1

Yeah. If everybody else is going to be connected in an AI way and you feel like you would be at a strategic disadvantage by not doing so, does that become a motivator for people to kind of get on board with a new system?

Shawn Vadala
CFO, Mettler-Toledo International

Like any new technology, I think most of our customers are going to want to understand it. They're going to want to try it. They're going to want to invest in it, and then if they have success, then they're going to double down on it. I think, I would imagine a lot of them, I mean, we can see it with the engagement we have with customers at the moment, that the number of conversations are increasing quite a bit in this area. I just think, for what we do, we're very well positioned for it, given that breadth, given that software layer, et cetera.

Speaker 1

Yep. Okay. Maybe let's just talk about the outlook for 2027, because that was new for the 3Q call, and we certainly got into a little bit of it at the Investor Day. The guide for 2027 is 5% local currency. That would put it on par with where 2026 seems like it's pointed. Then by segment, that's Lab up high singles, mid-singles for Industrial, and then food retail would be low single digit. That generally makes sense. I think the part that maybe strikes me as an interesting assumption is just on Industrial or in Industrial, because product inspection, the outlook is for low to mid-singles, and we were at the product inspection facility, and everything looks like it's going really, really well.

The comps are going to be meaningful. Is that really the basis for the starting point that says, "Hey, we should think about something maybe lower than mid-singles for 2027 as we sit in 2026"?

Shawn Vadala
CFO, Mettler-Toledo International

Yeah. I think we are kind of looking at First of all, in Q4, we have line of sight, right? It's going to be, I think we grew, I think it was it double digit the last two years in a row? I'm looking at Adam here, in Q4 for product inspection. We're lapping some comps already here in the fourth quarter, so our growth will be most likely pretty muted in the fourth quarter. As we look to next year, that kind of influences us a little bit, just with we are coming off a couple years of higher growth. We are going to be somewhat tied to our customer capital plans here. We acknowledge it's 70% of the business is food manufacturing, so it's always a little bit difficult to tell at what pace they're going to invest.

But when you step back from it, we've been competing extremely well in maybe arguably a softer market here. I think as we've kind of increased our TAM and really kind of gone after the mid-market more in the last few years, I think that's been very successful. You saw a lot of examples of new innovation there, new innovation that targets that mid-market, but also now coming out with new products at the premium level, like really the highest end of metal detection, X-ray. These are products that are just released. I have to believe that these are going to also help in terms of growth for next year. You could see a little bit the excitement and enthusiasm from our team the other day.

And I think the market is also receiving it very well too. I do feel good about our portfolio and our team and our ability to execute. I also think that within food, there's a lot of opportunity that you also heard too, right? There are going to be rethinking of package sizes and more protein offerings and stuff that kind of fits a GLP-1 diet, and all that actually creates a lot of investment as people are rethinking their packaging and their production lines. I do think that there's good opportunity for us here as well too. So again, we're probably a little bit more modest just given some of the comps, but we do have a lot of good things as well for the future.

Speaker 1

Irons in the fire, as they say.

Shawn Vadala
CFO, Mettler-Toledo International

Yeah, exactly.

Speaker 1

Yeah. Okay. Okay, then maybe just touching on China. China is another area of the business where things are going pretty well. In the first half of the year, it felt like that was the setup for the second half of the year. What has played out the way that you thought it would, then what is maybe different? There is sort of a similar version of a question to the last one, which is, how do you think about next year's growth outlook for China, just given the comp that you will be dealing with, but also just that you are seeing a lot of the good stuff going on in China in the second half?

Shawn Vadala
CFO, Mettler-Toledo International

Yeah. I think we started the year kind of with modest expectations, but certainly hoping to see better growth this year. Even during the downturn, I think we have been very consistent with our views on China. We have always viewed this as an attractive end market for us. We are, I think, just very well positioned in the country in terms of the end markets that we focus on. I think they are very well aligned with the strategic priorities in the country, whether it be the pharmaceutical industry, but also some of the hot segments like clean energy, which has subcategories like batteries, is a really good example. We have a great footprint there in terms of what we sell in China, we largely make in China too. I think that is important.

The kind of who we are selling to, about 70% of our business there is sold to private companies within China, with probably 10%-15% sold to multinationals. So, I think that helps us from a sustainability perspective as well. As we think about now the year. The thing that I really liked at the beginning of the year is we are starting to see early signs of the industrial business recovering, and that is important. Our China business is overweighted to industrial, particularly core industrial. We are actually underweighted on the product inspection side. This really gets to the heart of production and manufacturing, the economy. Yes, it is our core segments, so we have some secular exposures, but it is still like, are people making stuff there?

Speaker 1

Since it's at the root of the business.

Shawn Vadala
CFO, Mettler-Toledo International

Yeah. What was nice to me is that I think a few years back when the economy reset, there were pockets of overcapacity in certain industries, right? What was nice to see is that these industries kind of worked through that, and now they kind of grew back into that, and then we're seeing, I think, more organic growth and sustainable growth coming out of it. With that being said, we know that things in China can always change very quickly in either direction, but it's nice to see that we're kind of going in the right direction at the moment. At the beginning of the year, I think in Q4 a year ago, we kind of grew for the first time in industrial in a while.

We started to talk about that as like an early sign that things might be moving in the right direction. In Q1, we saw that industrial business grow high single digits, and then for the second half of the year, that industrial business is now growing mid-teens. If you think about lab has been a little bit of a kind of a laggard to that. In the first half of the year, it was flattish, maybe down slightly Q1, up slightly Q2. We grew high single digits in Q3, and then in Q4, our guidance is for mid-teens. You can kind of see we're really exiting the year with a lot of momentum. I expect that momentum will carry into the beginning of the year, but we're going to start lapping more difficult comps now on the industrial side.

Again, we're just being a little bit more cautious in how we guide China right now, knowing that things can always change quickly and that we're lapping these comps. Just to be clear, we're not seeing anything today that says things are going to slow down.

Speaker 1

Change for the worse.

Shawn Vadala
CFO, Mettler-Toledo International

Yeah. I mean, if you look at how businesses are investing in China, they're very much in the strengths of our portfolio. It keeps on coming back to they're moving as fast as anybody with automated solutions, they're moving as fast as anybody with digital solutions, and it really plays to the strength of our portfolio. We do feel very good about this. And with our LRP, we were also, I think, a little bit more modest here and just said, "Hey, it's a long-term thing. We'll be right around corporate average, and we should be fine." But of course, there's a bull case on it as well too, and we'll see how it plays out.

Speaker 1

Yeah. Okay. What about the market share environment in China? Do you still see there being good opportunity? I mean, I would imagine that as China emerges from the funk that it's been in, or the quasi-funk that it's been in, that maybe there are fewer mom and pop or regional players, whatever you want to call them, that are just sort of easy targets for Mettler, to just sort of do what you need to do or do what you like to do. Is that still a dynamic that is going to work for you? I guess, how would you count on market share as something to augment your sort of natural organic growth over the next couple of years?

Shawn Vadala
CFO, Mettler-Toledo International

Yeah. I think our market share is relatively similar to our corporate average in China for the most part, but we tend to have a higher relative market share to the number two. The markets tend to be more fragmented there, especially on the industrial side, and that plays well for us. And then, with us having significant R&D capabilities in China, we're able to really compete at maybe not only the mid-market level, but the lower part of mid-market to really make sure we're competing with that segment of the market as well too. And we've always had different strategies to make sure that we're not taking anything for granted in terms of the competitive environment. And I just feel like, hey, in the end, if you're bringing value to your customer, then that's the key, right?

Back to just being in China recently, we had a great trip, tons of energy, but they're just so proud of all the innovation that they're coming out with every year. I mean, it's amazing to see the progress that can be made from one year to the next internally, just with innovation topics and time to market on things, and it's actually stuff that we can leverage globally as well too, in terms of just that R&D agility. A lot of good things there. I think we're competing very well. I think you can kind of see it in the numbers.

I can't speak necessarily for all the mom and pops out there. It's always been like that, but I kind of feel like as a company our size, we can continue to invest much more heavily in the things that are really going to move the needle, like this digital solutions and automated solutions. I think that's the key .

Speaker 1

Do you see competitive risk to the Rainin business in China from local players? I get that question a lot just when it comes to where are you most vulnerable or where companies in the space most vulnerable to China?

Shawn Vadala
CFO, Mettler-Toledo International

Yeah. The answer is actually no different than a lot of other businesses, right? If we are not differentiated, then that would be a much more difficult situation. But in terms of what we are doing with pipettes and where we play, we are not trying to do everything, right? We carved out our niche in liquid handling, where it is the area where customers really care about quality, they really care about precision, and that is what we are going after. If you start going after a more like the universal tip environment, that is going to be much more competitive. That is going to be more price-sensitive. But what we do, it is a nichey segment. If I look at our liquid handling business in China at the moment, it is actually growing. It is growing recently very well.

What we do, like a lot of other things in China, is we have on-site R&D capabilities to also go after some of these solutions that are also important for the local market when it comes to liquid handling. It has been actually a very good story for us. It is a great part of how we think about M&A in general. It has been probably 25 years since we acquired Rainin, but the capabilities we have developed globally since we acquired Rainin has been really impressive. China is, I think, a very important part of that story.

I would say too, the last thing on liquid handling is it is neat to see how many new. It is another example of where we have a lot of new products coming out in the market. You have probably heard a few of these examples, and they are very differentiated.

Speaker 1

Yeah. To your point, the results kind of lay bare the fact that whatever competitive pressures you are seeing seemingly are manageable. I mean, the Rainin business has quite honestly grown faster than I would think a pipette business might in a lot of historical periods there. So, I understand what you are saying.

Okay. Maybe just, we are getting down to it here, so I want to make sure I touch on the LRP, which you updated at the Investor Day. The idea is kind of for like 6%+ organic growth, 100 basis points of op margin expansion, and then that can drive mid-teens EPS growth. On the 6% organic, so that is 200 basis points of pricing roughly and 400 basis points of volume. If you kind of divide the business into the lab side and the industrial side, what would be the expectation going forward for the makeup of those two components?

Shawn Vadala
CFO, Mettler-Toledo International

Yeah. On the lab side, we would expect to do probably high single digit. On the industrial side, there's maybe two pieces, right? There's the core industrial side, which would be around corporate average, and then the product inspection side below corporate average.

Speaker 1

Okay. On the op margin side, one of the questions that I also get on Mettler is just where do the margin opportunities continue to come from for this company? I mean, it's just a factual statement that your op margin expansion has over the years been above average. How do those opportunities for the next three to five years look different or the same as they have for, I don't know, the last five to 10?

Shawn Vadala
CFO, Mettler-Toledo International

Yeah. I mean, I think historically, we've always been. I feel very good about our history in terms of expanding margins. I think the last three or four years have been more challenging, just given the lack of volume we've seen in the business or just the industry. But I think despite that and despite all the headwinds that we've had with topics like tariffs and all these other things, I feel actually quite good about our ability to deliver what we've delivered in margins in recent years. Going forward, it's very much going to be about getting that volume growth back. Our incremental margins are very good, right? If you can see it kind of in our gross margin. So, once we get the volumes going, our incrementals will really help out a lot. But we have a lot of levers to get there too.

I think the businesses that are going to grow the fastest in the future, according to our expectations, have higher margins. We also, the way that we invest in innovation resonates also in our margin, right? If you're creating, enhancing that value proposition for your customer, there's going to just be a more natural willingness to pay for a product. I think we feel very good about our value proposition and our pricing program, and then we take that and we can reinvest in the business. We can reinvest in innovation for the future. We talked a lot about SternDrive at the investor day. That's obviously another lever. This whole Blue Ocean program and what it does and how we use AI internally, it's just going to make us increasingly more productive as an organization.

I feel like there's a lot of levers here, and I think we understand the playbook. Each year will be a little bit different. I think when we step back, we know what we got to do, and I think we have, most importantly, the culture of continuous improvement to kind of go after it.

Speaker 1

Last question for you on that point. Is it correct to think that 4%-5% organic growth is the point at which the leverage really starts to show up in the model?

Shawn Vadala
CFO, Mettler-Toledo International

Yeah. I think that's right. I think below that, I mean, you've seen [crosstalk] You've seen over the last few years what it could look like in different scenarios.

Speaker 1

Okay. Shawn, it is always great to see you. I really appreciate you coming during a busy period. Thanks a bunch.

Shawn Vadala
CFO, Mettler-Toledo International

Thanks for hosting us. Great to see you too.

Speaker 1

Thank you.